The thiazolidinedione rosiglitazone, a peroxisome proliferator activated receptor gamma (PPARγ) agonist, is an insulin sensitizing agent that improves glycaemic control and a variety of other metabolic disturbances in patients with type 2 diabetes. This evidence concerns the gene PPARG and type 2 diabetes mellitus.